Search | Clinical Trials Finder

Conditions: Peripheral Arterial Disease (PAD), Amputation, Thrombosis, Thrombosis (Stent Thrombosis), Platelet Aggregation Inhibitors, Thromboelastography (TEG), PRU(Platelet Reactivity Unit)
Interventions: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, Thromboelastography with Platelet Mapping; Drug · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Salem, Massachusetts

Conditions: NSCLC (Non-small Cell Lung Cancer), Metastatic NSCLC - Non-Small Cell Lung Cancer
Interventions: Core Needle, Forceps, or Punch Biopsy; Procedure
Lead sponsor: Elephas; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Frederick, Maryland • Shirley, New York + 4 more

Conditions: Breast Cancer
Interventions: PEAK PlasmaBlade, Traditional Electrosurgery with scalpel; Device · Procedure
Lead sponsor: Medtronic Surgical Technologies; Industry
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Mountain View, California

Conditions: Progressive Metastatic Castrate Resistant Prostate Cancer
Interventions: Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD, JSB462 Dose 1 QD, JSB462 Dose 2 QD, JSB462 QD, Standard of Care (SoC); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 8
States / cities: Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 5 more

Conditions: Colorectal Liver Metastases
Interventions: Microwave ablation; Device
Lead sponsor: Society of Interventional Oncology; Other
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Miami, Florida • Rochester, Minnesota • New York, New York + 2 more

Conditions: COVID-19
Interventions: PF-07304814, Placebo, Remdesivir; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 31
States / cities: Chula Vista, California • Los Angeles, California • Mather, California + 23 more

Conditions: Congestive Heart Failure
Interventions: Drug therapy for HF, NT-proBNP guided HF therapy; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Patient Adherence, HIV
Interventions: SMS Text Message Reminder; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 16 Years to 29 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Uveitis, Infectious Disease
Interventions: Metagenomic Deep Sequencing (MDS), Standard of Care (SOC); Device · Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer, Non Small Cell Lung Carcinoma
Interventions: azacytidine, carboplatin, paclitaxel, durvalumab, cisplatin, gemcitabine, pemetrexed; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: SAR445088 (IV), SAR445088 (SC); Drug
Lead sponsor: Bioverativ, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Fairway, Kansas + 2 more

Conditions: Individuals With Serious Mental Illness Leaving Jails
Interventions: Peer navigation intervention; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions: PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo); Drug · Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 8
States / cities: Beverly Hills, California • Fort Myers, Florida • Orlando, Florida + 4 more

Conditions: Peritoneal Carcinomatosis, Gastrointestinal Peritoneal Carcinomatosis
Interventions: Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples); Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Orange, California

Conditions: Aging
Interventions: Motor Practice of a Standing Serial Reaction Time Task; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 95 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
Interventions: Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 13
States / cities: Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more

Conditions: Thyroglossal Duct Cysts
Interventions: Post-surgical drain, No post-surgical drain; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 3 Years to 17 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Hartford, Connecticut • Chicago, Illinois + 2 more

Conditions: Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastasis Colon Cancer, Colorectal Cancer
Interventions: Y90 TARE, PET/CT, PET/MRI; Radiation · Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions: CF-301, Placebo; Biological · Drug
Lead sponsor: ContraFect; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 31
States / cities: Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more

Conditions: Prostate Cancer
Interventions: 18F-rhPSMA-7.3; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Systemic Sclerosis (SSc), Calcinosis Cutis
Interventions: Sodium Thiosulfate (STS), Sodium Thiosulfate Injection; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metastatic Colorectal Cancer
Interventions: BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 4
States / cities: New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Depemokimab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 981 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 42
States / cities: Bakersfield, California • Modesto, California • Newport Beach, California + 34 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus, Pegasys, RO4588161; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more

Search by objective public record fields.

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)

PEAK PlasmaBlade™ 4.0 Versus Traditional Electrosurgery in Lumpectomy

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting.

Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth

Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Peer Navigation for Individuals With Serious Mental Illness Leaving Jail

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis

Does Overpractice Improve Motor Learning?

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

Assessing Post-operative Outcomes After Children's Sistrunk Procedure With or Without a Drain

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.